Company news: Lighthouse Learning and Shire
The ACCME awarded provisional two-year accreditation to Lighthouse Learning, the educational content provider which develops and sells CME curricula without accepting commercial funding. In 2011, Lighthouse said, it conducted activities with other organizations serving as joint sponsor—Annenberg Center for Health Sciences at Eisenhower and Oakstone Medical Publishing/CMEinfo. The firm was started last year by a Harvard neurologist and two executives.
Shire received FDA approval for Firazyr to treat acute attacks from hereditary angioedema (HAE), a rare swelling disorder. The drug's self-injectable formulation may give it a marketing edge over HAE products Berinert, from CSL Behring, which is administered by IV infusion, and Kalbitor, from Dyax, which is injectable but must be given by a doctor. Cinryze, from ViroPharma, is self-administered by patients every three to four days to prevent HAE attacks. A fifth HAE drug, Rhucin (marketed as Ruconest in Europe), is in phase III trials and is being developed by Pharming NV.